The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma

被引:61
作者
Adams, Amy L. [1 ]
Eltoum, Isam [1 ]
Krontiras, Helen [2 ]
Wang, Wenquan [3 ,4 ]
Chhieng, David C. [1 ]
机构
[1] Univ Alabama, Dept Pathol, Birmingham, AL 35249 USA
[2] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA
[3] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA
[4] Univ Alabama, Ctr Comprehens Canc, Bioinformat Unit, Birmingham, AL 35294 USA
关键词
breast cancer; estrogen receptor; HER2/neu; neo-adjuvant chemotherapy; progesterone receptor;
D O I
10.1111/j.1524-4741.2007.00544.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of neoadjuvant chemotherapy prior to surgical resection for breast cancer is no longer restricted to patients with locally advanced disease. As preoperative treatment becomes more common, the question arises whether or not such therapy changes important tumor characteristics. The objective of our study is to compare histological grade, hormone receptor status, and HER2/neu expression pre- and post-therapy patients receiving preoperative neo-adjuvant chemotherapy. Forty patients status post-neoadjuvant treatment who had available archived pathologic material pre- and post-therapy were identified. Glass slides were reviewed retrospectively, and tumor grade, hormone receptor status, and HER2/neu expression were compared between the pre- and post-therapy specimens. No significant differences were noted between the pre- and post-specimens for two of the three parameters comprising the modified Bloom-Richardson grade, including degree of tubule formation (p = 0.062) and nuclear pleomorphism (p = 0.086). For mitotic activity, a decrease in score was observed between pre- and post-therapy specimens which was statistically significant (p = 0.021). However, there was no significant difference in the overall modified Bloom-Richardson grade (p = 0.118). Information was available regarding hormone receptor and HER2/neu status in 26 patients (65%). There was no significant difference between pre- and post-treatment specimens for hormone receptor status. However, there were more patients with HER2/neu overexpression after receiving neoadjuvant therapy (p = 0.027). Neoadjuvant therapy resulted in a significant decrease in mitotic count and an increase in the proportion of patients with Her2/neu overexpression. No significant changes were noted for the degree of tubule formation, nuclear pleomorphism, overall Bloom-Richardson score, and hormone receptor status. However, small sample size may be a limitation of these results.
引用
收藏
页码:141 / 146
页数:6
相关论文
共 27 条
[21]   Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy [J].
Taucher, S ;
Rudas, M ;
Gnant, M ;
Thomanek, K ;
Dubsky, P ;
Roka, S ;
Bachleitner, T ;
Kandioler, D ;
Wenzel, C ;
Steger, G ;
Mittlböck, M ;
Jakesz, R .
ENDOCRINE-RELATED CANCER, 2003, 10 (01) :91-98
[22]   Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma - A randomized study [J].
Vaillancourt, L ;
Tetu, B ;
Fradet, Y ;
Dupont, A ;
Gomez, J ;
Cusan, L ;
Suburu, ER ;
Diamond, P ;
Candas, B ;
Labrie, F .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (01) :86-93
[23]  
VANDEVOORDE WM, 1994, CANCER-AM CANCER SOC, V74, P3164, DOI 10.1002/1097-0142(19941215)74:12<3164::AID-CNCR2820741216>3.0.CO
[24]  
2-X
[25]   Stability of the HER2 gene after primary chemotherapy in advanced breast cancer [J].
Varga, Z ;
Caduff, R ;
Pestalozzi, B .
VIRCHOWS ARCHIV, 2005, 446 (02) :136-141
[26]   HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process [J].
Vincent-Salomon, A ;
Jouve, M ;
Genin, P ;
Fréneaux, P ;
Sigal-Zafrani, B ;
Caly, M ;
Beuzeboc, P ;
Pouillart, P ;
Sastre-Garau, X .
CANCER, 2002, 94 (08) :2169-2173
[27]  
WALLER U, 1960, Pathol Microbiol (Basel), V23, P283, DOI 10.1159/000160950